Adam Ritchie

Dr Adam Ritchie serves as a Senior Vaccinologist at the University of Oxford's Jenner Institute and Lecturer in Human Science at St Catherine's College. His work focuses on translating academic vaccine research into real-world impact through the development, manufacture, and clinical testing of candidates for rabies, Epstein-Barr virus (EBV), and SARS-CoV-2.

Education: Holds a BSc, PhD, and Fellow of the Higher Education Academy (FHEA) qualification. His research spans vaccine development, clinical trial design, regulatory affairs, and public policy through Vax-Hub Global. Key interests include adenovirus-vectored platforms, scalable manufacturing processes, and addressing global health challenges in resource-limited settings.

Analysis of his 2020-2025 publications reveals a cohesive research trajectory centered on ChAdOx1-vectored vaccines. Dominant themes include prime-boost regimens, intranasal delivery systems, cost-effectiveness modeling for low-income countries, and material science applications for vaccine stabilization. His work bridges laboratory innovation with implementation science, particularly in rabies prophylaxis and pandemic response.

Ritchie actively contributes to the Douglas Research Group at the Jenner Institute and global vaccine initiatives through Vax-Hub. His collaborative work appears in high-impact journals including The Lancet, Nature Medicine, and Vaccine, with emphasis on clinical translation and equitable vaccine access.